Bolivia Medical Device Inspections by AGEMED and SEDES: Enforcement and Penalty Outlook

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Inspection activity by AGEMED is carried out in coordination with the Departmental Health Services, known as SEDES, across the nine departments of Bolivia, covering warehouses, commercial premises, and administrative offices. The consequences of violations have their legal foundation in Article 59 of Ley N° 1737 of 17 December 1996, under which conduct that violates the law and its implementing regulations, including speculation and hoarding, is punishable. GRZAN draws one boundary here: public sources do not show a unified official quantified standard for device-specific penalties in Bolivia, such as fine percentages or the triggers for revoking permits. This column therefore provides no specific penalty figures, because where no official source for an amount or a percentage can be found, we do not write one. What can be stated with confidence is that the enforcement pathway exists, that it is exercised jointly by the national and departmental levels, and that the practical exposure of an importer is highest in its own warehouses and points of sale.

The departmental structure matters for planning. SEDES operate in each of the nine departments, so the same product can face inspection teams with different working styles in La Paz, Santa Cruz, or Cochabamba, and an importer with depots in more than one department must assume that each site will be visited on its own schedule. GRZAN recommends aligning the self-inspection program with the physical footprint: every storage site gets the same checklist, the same document set on hand, and the same trained contact person, so that compliance does not depend on which city the inspector walks into. The manufacturer, normally outside Bolivia, depends entirely on the quality of this local machinery, which is why the distribution agreement provisions described below are not boilerplate.

2. Legal basis

RegulationReference numberPublication dateProvision
Ley del Medicamento (medicines law)Ley N° 173717 December 1996Article 59
Decreto Supremo (establishing AGEMED)Decreto Supremo N° 290521 September 2016Article 2
Manual para Registro Sanitario de Dispositivos MédicosResolución Ministerial N° 010Current version as published on the AGEMED websiteSection 2.6
Decreto Supremo (implementing regulation of the medicines law)Decreto Supremo N° 2523530 November 1998Article 149

3. Expert insights

Insight one: inspection is a routine mechanism without a notice period. Section 2.6 of the Manual allows AGEMED to visit company warehouses at any time to verify products. The coordinated SEDES inspections extend this coverage across a wider set of premises and departments. The consequence is that the compliant state must be the normal state, not an inspection-ready state assembled for the occasion. Stock that is correctly marked, filed documents that are current, and a staff member who knows where records live are what an inspector actually sees, and no advance notice would change that picture. Readiness is therefore a property of the everyday process, measured by how the warehouse looks on an ordinary Tuesday, not by the quality of the response mounted once a visit is announced.

Insight two: the official description of penalty types is principled rather than quantified. Public legal question-and-answer sources summarize the penalties in Bolivia as economic sanctions, product confiscation, and up to the cancellation of import and operating permits. This summary is consistent with the legal foundation of Article 59, but it lacks quotable quantified standards. The GRZAN approach in projects is to prepare against the principled wording, and to treat the specific penalty as a matter for the written determination of the competent authority in each case, keeping internal risk registers free of invented numbers.

Insight three: violation risk concentrates in three points that companies can self-check. Drawing together the preceding articles of this series, the high-frequency violations are: packaging without the registration number, under Section 5.7.1; packaging without the Bolivian enterprise identification, under Article 149 of Decreto Supremo N° 25235; and the annual enterprise review not completed by 31 December, under Section 5.7.2. All three can be verified by the company itself, which makes them the cheapest risks to eliminate, and each of them is visible to an inspector within minutes of entering the premises. A quarterly self-inspection sheet built around exactly these three items, signed and dated by the warehouse manager, is the cheapest insurance available in this market.

4. Practical recommendations

  1. Turn the three high-frequency violation points into a quarterly self-inspection sheet, executed by the importer with records returned to the manufacturer, so that both parties see the same compliance picture on the same calendar.
  2. Require the importer to establish an inspection cooperation procedure, naming the responsible person and the document retrieval path, so that an unannounced visit is handled by routine rather than improvisation.
  3. Allocate liability for violations in the distribution agreement, especially for sanctions caused by the conduct of the importer, so that responsibility follows control and recovery of losses does not depend on negotiation after the fact.

One organizational detail completes the picture: the inspection day itself. The responsible person should know what the inspector is entitled to see, where the certificates, the import documents, and the marking records are kept, and who must be called at the manufacturer before any statement about the product is made. A short one-page instruction, laminated and kept at the warehouse desk, is enough. GRZAN has seen inspection outcomes turn on this preparation: two importers with identical stock can receive very different treatment, because one can produce a marked unit, a current certificate, and a named contact within minutes, while the other searches for a file while the inspector waits.

5. Verification checklist

  • □ Does the packaging carry the registration number, under Section 5.7.1?
  • □ Does the packaging carry the Bolivian enterprise identification, under Article 149?
  • □ Was the annual enterprise review completed before 31 December of the year?
  • □ Has the importer established an inspection cooperation procedure?
  • □ Does the distribution agreement allocate liability for violations?

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers, importers, and authorized representatives with sanitary registration, inspection readiness, and post-market compliance in Bolivia. For assistance with this topic, contact info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail